For research use only. Not for therapeutic Use.
Taragarestrant meglumine (Cat No.: I042492) is a selective estrogen receptor degrader (SERD) formulated as a meglumine salt to enhance solubility and bioavailability. It binds to estrogen receptor alpha (ERα), promoting its degradation and blocking estrogen-driven signaling pathways involved in hormone receptor–positive breast cancer. Taragarestrant offers potential advantages over earlier SERDs like fulvestrant, including oral bioavailability and improved pharmacokinetics. It is under investigation for use in treating ER-positive, HER2-negative breast cancer, particularly in patients with endocrine resistance or advanced metastatic disease.
| CAS Number | 2446618-18-2 |
| Synonyms | (E)-3-[3,5-dichloro-4-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol |
| Molecular Formula | C32H42Cl2FN3O7 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H25Cl2FN2O2.C7H17NO5/c1-14-10-17-16-6-4-5-7-20(16)29-23(17)24(30(14)13-25(2,3)28)22-18(26)11-15(12-19(22)27)8-9-21(31)32;1-8-2-4(10)6(12)7(13)5(11)3-9/h4-9,11-12,14,24,29H,10,13H2,1-3H3,(H,31,32);4-13H,2-3H2,1H3/b9-8+;/t14-,24-;4-,5+,6+,7+/m10/s1 |
| InChIKey | QLOWUROBGXPIGD-DAIKAQOVSA-N |
| SMILES | CC1CC2=C(C(N1CC(C)(C)F)C3=C(C=C(C=C3Cl)C=CC(=O)O)Cl)NC4=CC=CC=C24.CNCC(C(C(C(CO)O)O)O)O |
| Reference | [1]. Lin WY, et, al. Abstract 5776: Pharmacologic and PK/PD study of D-0502: An orally bioavailable SERD with potent antitumor activity in ER-positive breast cancer cell lines and xenograft models. 2018 Jul 1;78(13):5776. [2]. WHO Drug Information. International Nonproprietary Names for Pharmaceutical. |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
